Here's Why Regeneron’s Stock Is Worth More Than Its Coronavirus Work
Regeneron's (NASDAQ: REGN) stock has increased by 34% in 2020 as the company and its partner Sanofi (NASDAQ: SNY) initiated two large scale phase 2/3 clinical trials in March where it is providing an existing drug, Kevzara, to treat patients with severe COVID-19, the disease caused by the novel coronavirus. This development has investors optimistic about its prospects. But Regeneron's financial performance for the full year will be driven by the company's core business of treating eye diseases, asthma, eczema, and cancer.
Let's take a closer look at the biotech stock's main revenue drivers to decide if it's a buy today.
Image Source: Getty Images
Source Fool.com
